CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard M. Walls; Jamie B. Oughton; Anthony J. Chalmers; Sarah Brown; Fiona Collinson; Martin D. Forster; Kevin N. Franks; Alexandra Gilbert; Gerard G. Hanna; Nicola Hannaway; Stephen Harrow; Tom Haswell; Crispin T. Hiley; Samantha Hinsley; Matthew Krebs; Geraldine Murden; Rachel Phillip; Anderson J. Ryan; Ahmed Salem; David Sebag-Montefoire; Paul Shaw; Chris J. Twelves; Katrina Walker; Robin J. Young; Corinne Faivre-Finn; Alastair Greystoke

doi:10.1016/j.ctro.2020.09.006

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard M. Walls, Jamie B. Oughton, Anthony J. Chalmers, Sarah Brown, Fiona Collinson, Martin D. Forster, Kevin N. Franks, Alexandra Gilbert, Gerard G. Hanna, Nicola Hannaway, Stephen Harrow, Tom Haswell, Crispin T. Hiley, Samantha Hinsley, Matthew Krebs, Geraldine Murden, Rachel Phillip, Anderson J. Ryan, Ahmed Salem, David Sebag-MontefoirePaul Shaw, Chris J. Twelves, Katrina Walker, Robin J. Young, Corinne Faivre-Finn, Alastair Greystoke

Research output: Contribution to journal › Article › peer-review

Abstract

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Original language	English
Pages (from-to)	61-66
Number of pages	6
Journal	Clinical and translational radiation oncology
Volume	25
DOIs	https://doi.org/10.1016/j.ctro.2020.09.006
Publication status	Published - 1 Nov 2020

Keywords

Continual reassessment method
DNA damage repair inhibitor
Non-small cell lung cancer
Platform trial
Sequential chemoradiotherapy

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctro.2020.09.006

Cite this

Walls, G. M., Oughton, J. B., Chalmers, A. J., Brown, S., Collinson, F., Forster, M. D., Franks, K. N., Gilbert, A., Hanna, G. G., Hannaway, N., Harrow, S., Haswell, T., Hiley, C. T., Hinsley, S., Krebs, M., Murden, G., Phillip, R., Ryan, A. J., Salem, A., ... Greystoke, A. (2020). CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and translational radiation oncology, 25, 61-66. https://doi.org/10.1016/j.ctro.2020.09.006

@article{d3c4c16892c640a99707cff02bf3bedf,

title = "CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer",

abstract = "Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for {\textquoteleft}gold standard{\textquoteright} treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.",

keywords = "Continual reassessment method, DNA damage repair inhibitor, Non-small cell lung cancer, Platform trial, Sequential chemoradiotherapy",

author = "Walls, {Gerard M.} and Oughton, {Jamie B.} and Chalmers, {Anthony J.} and Sarah Brown and Fiona Collinson and Forster, {Martin D.} and Franks, {Kevin N.} and Alexandra Gilbert and Hanna, {Gerard G.} and Nicola Hannaway and Stephen Harrow and Tom Haswell and Hiley, {Crispin T.} and Samantha Hinsley and Matthew Krebs and Geraldine Murden and Rachel Phillip and Ryan, {Anderson J.} and Ahmed Salem and David Sebag-Montefoire and Paul Shaw and Twelves, {Chris J.} and Katrina Walker and Young, {Robin J.} and Corinne Faivre-Finn and Alastair Greystoke",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.ctro.2020.09.006",

language = "English",

volume = "25",

pages = "61--66",

journal = "Clinical and translational radiation oncology",

issn = "2405-6308",

publisher = "Elsevier BV",

}

Walls, GM, Oughton, JB, Chalmers, AJ, Brown, S, Collinson, F, Forster, MD, Franks, KN, Gilbert, A, Hanna, GG, Hannaway, N, Harrow, S, Haswell, T, Hiley, CT, Hinsley, S, Krebs, M, Murden, G, Phillip, R, Ryan, AJ, Salem, A, Sebag-Montefoire, D, Shaw, P, Twelves, CJ, Walker, K, Young, RJ, Faivre-Finn, C & Greystoke, A 2020, 'CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer', Clinical and translational radiation oncology, vol. 25, pp. 61-66. https://doi.org/10.1016/j.ctro.2020.09.006

TY - JOUR

T1 - CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

AU - Walls, Gerard M.

AU - Oughton, Jamie B.

AU - Chalmers, Anthony J.

AU - Brown, Sarah

AU - Collinson, Fiona

AU - Forster, Martin D.

AU - Franks, Kevin N.

AU - Gilbert, Alexandra

AU - Hanna, Gerard G.

AU - Hannaway, Nicola

AU - Harrow, Stephen

AU - Haswell, Tom

AU - Hiley, Crispin T.

AU - Hinsley, Samantha

AU - Krebs, Matthew

AU - Murden, Geraldine

AU - Phillip, Rachel

AU - Ryan, Anderson J.

AU - Salem, Ahmed

AU - Sebag-Montefoire, David

AU - Shaw, Paul

AU - Twelves, Chris J.

AU - Walker, Katrina

AU - Young, Robin J.

AU - Faivre-Finn, Corinne

AU - Greystoke, Alastair

PY - 2020/11/1

Y1 - 2020/11/1

N2 - Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

AB - Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

KW - Continual reassessment method

KW - DNA damage repair inhibitor

KW - Non-small cell lung cancer

KW - Platform trial

KW - Sequential chemoradiotherapy

UR - https://www.mendeley.com/catalogue/29f32141-56ac-3b63-9baa-eeab21926be2/

U2 - 10.1016/j.ctro.2020.09.006

DO - 10.1016/j.ctro.2020.09.006

M3 - Article

SN - 2405-6308

VL - 25

SP - 61

EP - 66

JO - Clinical and translational radiation oncology

JF - Clinical and translational radiation oncology

ER -

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this